Transglutaminase 6

Human neuronal transglutaminase

(TG6, recombinantly produced in insect cells)

250 µg 500 € available
1 mg 1500 € available

Art. No. T021
Synonym Neuronal Transglutaminase, TGy, TG6, TGase 6, protein-glutamine-γ-glutamyltransferase

neuronal transglutaminase TG6 T021 by Zedira
Molecular Weight 78 kDa
Source Recombinantly produced in insect cells
Purity > 95% [SDS-PAGE and Coomassie staining]
Activation His6-rhTG6 is a Ca2+-dependent enzyme.
Appearance White lyophilized solid.
Reagents The Transglutaminase is lyophilized from 10 mM Tris-HCl pH 8.2, 500 mM NaCl, 2 mM DTT. Sample contains sucrose.
Reconstitution Add the volume of water specified in the certificate of analysis under aliquotation to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots. For short term storage keep cooled on ice.
Application His6-rhTG6 catalyzes acyl transfer reactions from glutamine residues in proteins or peptides to primary amines, e. g. the formation of ε-(γ-glutamyl) lysine bonds between proteins by transferring the acyl group of a peptide-bound glutamine residue to the primary amino group of a peptide-bound lysine residue.
Storage T021 is stable for at least one year if stored at ≤ -20°C.
Avoid freeze-thaw cycles.
Reference(s) Fukui et al., FEBS J. 2013, 280:1420-9
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy